HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


XXL Impressions Supplement Memory Claims Impress FTC As False

This article was originally published in The Rose Sheet

Executive Summary

FTC announces agreements to settle complaints against six of nine defendants identified in an investigation of XXL Impressions' advertising for CogniPrin promoted for cognitive benefits and FlexiPrin product promoted to reduce joint paint and rebuild damaged joints and cartilage.

You may also be interested in...

'Free Trial' Offers Cost Marketers Of Supplements With Bogus Claims

FTC sends refunds totaling $60,791 to purchasers of Nobetes' product touted as diabetes treatment and $113,000 for purchases of FlexiPrin, a deceptively marketed joint pain supplement. Commission previously settled with both firms.

FDA Prioritizes Vinpocetine Decison After Animal Study Shows 'Developmental Toxicity'

Agency announces plan in statement by two deputy commissioners warning consumers about safety concerns regarding the semi-synthetic derivative of vincamine, "specifically concerns about the use of this ingredient by women of childbearing age." Recent findings by NIH National Toxicology Program's study with rats and rabbits indicate "vinpocetine may cause a miscarriage or harm fetal development," FDA says.

UAS Labs Expands Probioitic Portfolio: Health And Wellness Industry News

UAS Labs acquires Nebraska Cultures; ingredient supplier guilty in FDA undercover investigation; FTC cuts checks for bogus memory pill refunds; diaper rash cream recall; and kratom recall updates.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts